Feeds:
Posts
Comments

Archive for the ‘S-nitrosylation’ Category

Summary of Translational Medicine – e-Series A: Cardiovascular Diseases, Volume Four – Part 1

Summary of Translational Medicine – e-Series A: Cardiovascular Diseases, Volume Four – Part 1

Author and Curator: Larry H Bernstein, MD, FCAP

and

Curator: Aviva Lev-Ari, PhD, RN

Article ID #135: Summary of Translational Medicine – e-Series A: Cardiovascular Diseases, Volume Four – Part 1. Published on 4/28/2014

WordCloud Image Produced by Adam Tubman

 

Part 1 of Volume 4 in the e-series A: Cardiovascular Diseases and Translational Medicine, provides a foundation for grasping a rapidly developing surging scientific endeavor that is transcending laboratory hypothesis testing and providing guidelines to:

  • Target genomes and multiple nucleotide sequences involved in either coding or in regulation that might have an impact on complex diseases, not necessarily genetic in nature.
  • Target signaling pathways that are demonstrably maladjusted, activated or suppressed in many common and complex diseases, or in their progression.
  • Enable a reduction in failure due to toxicities in the later stages of clinical drug trials as a result of this science-based understanding.
  • Enable a reduction in complications from the improvement of machanical devices that have already had an impact on the practice of interventional procedures in cardiology, cardiac surgery, and radiological imaging, as well as improving laboratory diagnostics at the molecular level.
  • Enable the discovery of new drugs in the continuing emergence of drug resistance.
  • Enable the construction of critical pathways and better guidelines for patient management based on population outcomes data, that will be critically dependent on computational methods and large data-bases.

What has been presented can be essentially viewed in the following Table:

 

Summary Table for TM - Part 1

Summary Table for TM – Part 1

 

 

 

There are some developments that deserve additional development:

1. The importance of mitochondrial function in the activity state of the mitochondria in cellular work (combustion) is understood, and impairments of function are identified in diseases of muscle, cardiac contraction, nerve conduction, ion transport, water balance, and the cytoskeleton – beyond the disordered metabolism in cancer.  A more detailed explanation of the energetics that was elucidated based on the electron transport chain might also be in order.

2. The processes that are enabling a more full application of technology to a host of problems in the environment we live in and in disease modification is growing rapidly, and will change the face of medicine and its allied health sciences.

 

Electron Transport and Bioenergetics

Deferred for metabolomics topic

Synthetic Biology

Introduction to Synthetic Biology and Metabolic Engineering

Kristala L. J. Prather: Part-1    <iBiology > iBioSeminars > Biophysics & Chemical Biology >

http://www.ibiology.org Lecturers generously donate their time to prepare these lectures. The project is funded by NSF and NIGMS, and is supported by the ASCB and HHMI.
Dr. Prather explains that synthetic biology involves applying engineering principles to biological systems to build “biological machines”.

Dr. Prather has received numerous awards both for her innovative research and for excellence in teaching.  Learn more about how Kris became a scientist at
Prather 1: Synthetic Biology and Metabolic Engineering  2/6/14IntroductionLecture Overview In the first part of her lecture, Dr. Prather explains that synthetic biology involves applying engineering principles to biological systems to build “biological machines”. The key material in building these machines is synthetic DNA. Synthetic DNA can be added in different combinations to biological hosts, such as bacteria, turning them into chemical factories that can produce small molecules of choice. In Part 2, Prather describes how her lab used design principles to engineer E. coli that produce glucaric acid from glucose. Glucaric acid is not naturally produced in bacteria, so Prather and her colleagues “bioprospected” enzymes from other organisms and expressed them in E. coli to build the needed enzymatic pathway. Prather walks us through the many steps of optimizing the timing, localization and levels of enzyme expression to produce the greatest yield. Speaker Bio: Kristala Jones Prather received her S.B. degree from the Massachusetts Institute of Technology and her PhD at the University of California, Berkeley both in chemical engineering. Upon graduation, Prather joined the Merck Research Labs for 4 years before returning to academia. Prather is now an Associate Professor of Chemical Engineering at MIT and an investigator with the multi-university Synthetic Biology Engineering Reseach Center (SynBERC). Her lab designs and constructs novel synthetic pathways in microorganisms converting them into tiny factories for the production of small molecules. Dr. Prather has received numerous awards both for her innovative research and for excellence in teaching.

VIEW VIDEOS

https://www.youtube.com/watch?feature=player_embedded&v=ndThuqVumAk#t=0

https://www.youtube.com/watch?feature=player_embedded&v=ndThuqVumAk#t=12

https://www.youtube.com/watch?feature=player_embedded&v=ndThuqVumAk#t=74

https://www.youtube.com/watch?feature=player_embedded&v=ndThuqVumAk#t=129

https://www.youtube.com/watch?feature=player_embedded&v=ndThuqVumAk#t=168

https://www.youtube.com/watch?feature=player_embedded&v=ndThuqVumAk

 

II. Regulatory Effects of Mammalian microRNAs

Calcium Cycling in Synthetic and Contractile Phasic or Tonic Vascular Smooth Muscle Cells

in INTECH
Current Basic and Pathological Approaches to
the Function of Muscle Cells and Tissues – From Molecules to HumansLarissa Lipskaia, Isabelle Limon, Regis Bobe and Roger Hajjar
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/48240
1. Introduction
Calcium ions (Ca ) are present in low concentrations in the cytosol (~100 nM) and in high concentrations (in mM range) in both the extracellular medium and intracellular stores (mainly sarco/endo/plasmic reticulum, SR). This differential allows the calcium ion messenger that carries information
as diverse as contraction, metabolism, apoptosis, proliferation and/or hypertrophic growth. The mechanisms responsible for generating a Ca signal greatly differ from one cell type to another.
In the different types of vascular smooth muscle cells (VSMC), enormous variations do exist with regard to the mechanisms responsible for generating Ca signal. In each VSMC phenotype (synthetic/proliferating and contractile [1], tonic or phasic), the Ca signaling system is adapted to its particular function and is due to the specific patterns of expression and regulation of Ca.
For instance, in contractile VSMCs, the initiation of contractile events is driven by mem- brane depolarization; and the principal entry-point for extracellular Ca is the voltage-operated L-type calcium channel (LTCC). In contrast, in synthetic/proliferating VSMCs, the principal way-in for extracellular Ca is the store-operated calcium (SOC) channel.
Whatever the cell type, the calcium signal consists of  limited elevations of cytosolic free calcium ions in time and space. The calcium pump, sarco/endoplasmic reticulum Ca ATPase (SERCA), has a critical role in determining the frequency of SR Ca release by upload into the sarcoplasmic
sensitivity of  SR calcium channels, Ryanodin Receptor, RyR and Inositol tri-Phosphate Receptor, IP3R.
Synthetic VSMCs have a fibroblast appearance, proliferate readily, and synthesize increased levels of various extracellular matrix components, particularly fibronectin, collagen types I and III, and tropoelastin [1].
Contractile VSMCs have a muscle-like or spindle-shaped appearance and well-developed contractile apparatus resulting from the expression and intracellular accumulation of thick and thin muscle filaments [1].
Schematic representation of Calcium Cycling in Contractile and Proliferating VSMCs

Schematic representation of Calcium Cycling in Contractile and Proliferating VSMCs

 

Figure 1. Schematic representation of Calcium Cycling in Contractile and Proliferating VSMCs.

Left panel: schematic representation of calcium cycling in quiescent /contractile VSMCs. Contractile re-sponse is initiated by extracellular Ca influx due to activation of Receptor Operated Ca (through phosphoinositol-coupled receptor) or to activation of L-Type Calcium channels (through an increase in luminal pressure). Small increase of cytosolic due IP3 binding to IP3R (puff) or RyR activation by LTCC or ROC-dependent Ca influx leads to large SR Ca IP3R or RyR clusters (“Ca -induced Ca SR calcium pumps (both SERCA2a and SERCA2b are expressed in quiescent VSMCs), maintaining high concentration of cytosolic Ca and setting the sensitivity of RyR or IP3R for the next spike.
Contraction of VSMCs occurs during oscillatory Ca transient.
Middle panel: schematic representa tion of atherosclerotic vessel wall. Contractile VSMC are located in the media layer, synthetic VSMC are located in sub-endothelial intima.
Right panel: schematic representation of calcium cycling in quiescent /contractile VSMCs. Agonist binding to phosphoinositol-coupled receptor leads to the activation of IP3R resulting in large increase in cytosolic Ca calcium pumps (only SERCA2b, having low turnover and low affinity to Ca depletion leads to translocation of SR Ca sensor STIM1 towards PM, resulting in extracellular Ca influx though opening of Store Operated Channel (CRAC). Resulted steady state Ca transient is critical for activation of proliferation-related transcription factors ‘NFAT).
Abbreviations: PLC – phospholipase C; PM – plasma membrane; PP2B – Ca /calmodulin-activated protein phosphatase 2B (calcineurin); ROC- receptor activated channel; IP3 – inositol-1,4,5-trisphosphate, IP3R – inositol-1,4,5- trisphosphate receptor; RyR – ryanodine receptor; NFAT – nuclear factor of activated T-lymphocytes; VSMC – vascular smooth muscle cells; SERCA – sarco(endo)plasmic reticulum Ca sarcoplasmic reticulum.

 

Time for New DNA Synthesis and Sequencing Cost Curves

By Rob Carlson

I’ll start with the productivity plot, as this one isn’t new. For a discussion of the substantial performance increase in sequencing compared to Moore’s Law, as well as the difficulty of finding this data, please see this post. If nothing else, keep two features of the plot in mind: 1) the consistency of the pace of Moore’s Law and 2) the inconsistency and pace of sequencing productivity. Illumina appears to be the primary driver, and beneficiary, of improvements in productivity at the moment, especially if you are looking at share prices. It looks like the recently announced NextSeq and Hiseq instruments will provide substantially higher productivities (hand waving, I would say the next datum will come in another order of magnitude higher), but I think I need a bit more data before officially putting another point on the plot.

 

cost-of-oligo-and-gene-synthesis

cost-of-oligo-and-gene-synthesis

Illumina’s instruments are now responsible for such a high percentage of sequencing output that the company is effectively setting prices for the entire industry. Illumina is being pushed by competition to increase performance, but this does not necessarily translate into lower prices. It doesn’t behoove Illumina to drop prices at this point, and we won’t see any substantial decrease until a serious competitor shows up and starts threatening Illumina’s market share. The absence of real competition is the primary reason sequencing prices have flattened out over the last couple of data points.

Note that the oligo prices above are for column-based synthesis, and that oligos synthesized on arrays are much less expensive. However, array synthesis comes with the usual caveat that the quality is generally lower, unless you are getting your DNA from Agilent, which probably means you are getting your dsDNA from Gen9.

Note also that the distinction between the price of oligos and the price of double-stranded sDNA is becoming less useful. Whether you are ordering from Life/Thermo or from your local academic facility, the cost of producing oligos is now, in most cases, independent of their length. That’s because the cost of capital (including rent, insurance, labor, etc) is now more significant than the cost of goods. Consequently, the price reflects the cost of capital rather than the cost of goods. Moreover, the cost of the columns, reagents, and shipping tubes is certainly more than the cost of the atoms in the sDNA you are ostensibly paying for. Once you get into longer oligos (substantially larger than 50-mers) this relationship breaks down and the sDNA is more expensive. But, at this point in time, most people aren’t going to use longer oligos to assemble genes unless they have a tricky job that doesn’t work using short oligos.

Looking forward, I suspect oligos aren’t going to get much cheaper unless someone sorts out how to either 1) replace the requisite human labor and thereby reduce the cost of capital, or 2) finally replace the phosphoramidite chemistry that the industry relies upon.

IDT’s gBlocks come at prices that are constant across quite substantial ranges in length. Moreover, part of the decrease in price for these products is embedded in the fact that you are buying smaller chunks of DNA that you then must assemble and integrate into your organism of choice.

Someone who has purchased and assembled an absolutely enormous amount of sDNA over the last decade, suggested that if prices fell by another order of magnitude, he could switch completely to outsourced assembly. This is a potentially interesting “tipping point”. However, what this person really needs is sDNA integrated in a particular way into a particular genome operating in a particular host. The integration and testing of the new genome in the host organism is where most of the cost is. Given the wide variety of emerging applications, and the growing array of hosts/chassis, it isn’t clear that any given technology or firm will be able to provide arbitrary synthetic sequences incorporated into arbitrary hosts.

 TrackBack URL: http://www.synthesis.cc/cgi-bin/mt/mt-t.cgi/397

 

Startup to Strengthen Synthetic Biology and Regenerative Medicine Industries with Cutting Edge Cell Products

28 Nov 2013 | PR Web

Dr. Jon Rowley and Dr. Uplaksh Kumar, Co-Founders of RoosterBio, Inc., a newly formed biotech startup located in Frederick, are paving the way for even more innovation in the rapidly growing fields of Synthetic Biology and Regenerative Medicine. Synthetic Biology combines engineering principles with basic science to build biological products, including regenerative medicines and cellular therapies. Regenerative medicine is a broad definition for innovative medical therapies that will enable the body to repair, replace, restore and regenerate damaged or diseased cells, tissues and organs. Regenerative therapies that are in clinical trials today may enable repair of damaged heart muscle following heart attack, replacement of skin for burn victims, restoration of movement after spinal cord injury, regeneration of pancreatic tissue for insulin production in diabetics and provide new treatments for Parkinson’s and Alzheimer’s diseases, to name just a few applications.

While the potential of the field is promising, the pace of development has been slow. One main reason for this is that the living cells required for these therapies are cost-prohibitive and not supplied at volumes that support many research and product development efforts. RoosterBio will manufacture large quantities of standardized primary cells at high quality and low cost, which will quicken the pace of scientific discovery and translation to the clinic. “Our goal is to accelerate the development of products that incorporate living cells by providing abundant, affordable and high quality materials to researchers that are developing and commercializing these regenerative technologies” says Dr. Rowley

 

Life at the Speed of Light

http://kcpw.org/?powerpress_pinw=92027-podcast

NHMU Lecture featuring – J. Craig Venter, Ph.D.
Founder, Chairman, and CEO – J. Craig Venter Institute; Co-Founder and CEO, Synthetic Genomics Inc.

J. Craig Venter, Ph.D., is Founder, Chairman, and CEO of the J. Craig Venter Institute (JVCI), a not-for-profit, research organization dedicated to human, microbial, plant, synthetic and environmental research. He is also Co-Founder and CEO of Synthetic Genomics Inc. (SGI), a privately-held company dedicated to commercializing genomic-driven solutions to address global needs.

In 1998, Dr. Venter founded Celera Genomics to sequence the human genome using new tools and techniques he and his team developed.  This research culminated with the February 2001 publication of the human genome in the journal, Science. Dr. Venter and his team at JVCI continue to blaze new trails in genomics.  They have sequenced and a created a bacterial cell constructed with synthetic DNA,  putting humankind at the threshold of a new phase of biological research.  Whereas, we could  previously read the genetic code (sequencing genomes), we can now write the genetic code for designing new species.

The science of synthetic genomics will have a profound impact on society, including new methods for chemical and energy production, human health and medical advances, clean water, and new food and nutritional products. One of the most prolific scientists of the 21st century for his numerous pioneering advances in genomics,  he  guides us through this emerging field, detailing its origins, current challenges, and the potential positive advances.

His work on synthetic biology truly embodies the theme of “pushing the boundaries of life.”  Essentially, Venter is seeking to “write the software of life” to create microbes designed by humans rather than only through evolution. The potential benefits and risks of this new technology are enormous. It also requires us to examine, both scientifically and philosophically, the question of “What is life?”

J Craig Venter wants to digitize DNA and transmit the signal to teleport organisms

http://pharmaceuticalintelligence.com/2013/11/01/j-craig-venter-wants-to-digitize-dna-and-transmit-the-signal-to-teleport-organisms/

2013 Genomics: The Era Beyond the Sequencing of the Human Genome: Francis Collins, Craig Venter, Eric Lander, et al.

http://pharmaceuticalintelligence.com/2013/02/11/2013-genomics-the-era-beyond-the-sequencing-human-genome-francis-collins-craig-venter-eric-lander-et-al/

Human Longevity Inc (HLI) – $70M in Financing of Venter’s New Integrative Omics and Clinical Bioinformatics

http://pharmaceuticalintelligence.com/2014/03/05/human-longevity-inc-hli-70m-in-financing-of-venters-new-integrative-omics-and-clinical-bioinformatics/

 

 

Where Will the Century of Biology Lead Us?

By Randall Mayes

A technology trend analyst offers an overview of synthetic biology, its potential applications, obstacles to its development, and prospects for public approval.

  • In addition to boosting the economy, synthetic biology projects currently in development could have profound implications for the future of manufacturing, sustainability, and medicine.
  • Before society can fully reap the benefits of synthetic biology, however, the field requires development and faces a series of hurdles in the process. Do researchers have the scientific know-how and technical capabilities to develop the field?

Biology + Engineering = Synthetic Biology

Bioengineers aim to build synthetic biological systems using compatible standardized parts that behave predictably. Bioengineers synthesize DNA parts—oligonucleotides composed of 50–100 base pairs—which make specialized components that ultimately make a biological system. As biology becomes a true engineering discipline, bioengineers will create genomes using mass-produced modular units similar to the microelectronics and computer industries.

Currently, bioengineering projects cost millions of dollars and take years to develop products. For synthetic biology to become a Schumpeterian revolution, smaller companies will need to be able to afford to use bioengineering concepts for industrial applications. This will require standardized and automated processes.

A major challenge to developing synthetic biology is the complexity of biological systems. When bioengineers assemble synthetic parts, they must prevent cross talk between signals in other biological pathways. Until researchers better understand these undesired interactions that nature has already worked out, applications such as gene therapy will have unwanted side effects. Scientists do not fully understand the effects of environmental and developmental interaction on gene expression. Currently, bioengineers must repeatedly use trial and error to create predictable systems.

Similar to physics, synthetic biology requires the ability to model systems and quantify relationships between variables in biological systems at the molecular level.

The second major challenge to ensuring the success of synthetic biology is the development of enabling technologies. With genomes having billions of nucleotides, this requires fast, powerful, and cost-efficient computers. Moore’s law, named for Intel co-founder Gordon Moore, posits that computing power progresses at a predictable rate and that the number of components in integrated circuits doubles each year until its limits are reached. Since Moore’s prediction, computer power has increased at an exponential rate while pricing has declined.

DNA sequencers and synthesizers are necessary to identify genes and make synthetic DNA sequences. Bioengineer Robert Carlson calculated that the capabilities of DNA sequencers and synthesizers have followed a pattern similar to computing. This pattern, referred to as the Carlson Curve, projects that scientists are approaching the ability to sequence a human genome for $1,000, perhaps in 2020. Carlson calculated that the costs of reading and writing new genes and genomes are falling by a factor of two every 18–24 months. (see recent Carlson comment on requirement to read and write for a variety of limiting  conditions).

Startup to Strengthen Synthetic Biology and Regenerative Medicine Industries with Cutting Edge Cell Products

http://pharmaceuticalintelligence.com/2013/11/28/startup-to-strengthen-synthetic-biology-and-regenerative-medicine-industries-with-cutting-edge-cell-products/

Synthetic Biology: On Advanced Genome Interpretation for Gene Variants and Pathways: What is the Genetic Base of Atherosclerosis and Loss of Arterial Elasticity with Aging

http://pharmaceuticalintelligence.com/2013/05/17/synthetic-biology-on-advanced-genome-interpretation-for-gene-variants-and-pathways-what-is-the-genetic-base-of-atherosclerosis-and-loss-of-arterial-elasticity-with-aging/

Synthesizing Synthetic Biology: PLOS Collections

http://pharmaceuticalintelligence.com/2012/08/17/synthesizing-synthetic-biology-plos-collections/

Capturing ten-color ultrasharp images of synthetic DNA structures resembling numerals 0 to 9

http://pharmaceuticalintelligence.com/2014/02/05/capturing-ten-color-ultrasharp-images-of-synthetic-dna-structures-resembling-numerals-0-to-9/

Silencing Cancers with Synthetic siRNAs

http://pharmaceuticalintelligence.com/2013/12/09/silencing-cancers-with-synthetic-sirnas/

Genomics Now—and Beyond the Bubble

Futurists have touted the twenty-first century as the century of biology based primarily on the promise of genomics. Medical researchers aim to use variations within genes as biomarkers for diseases, personalized treatments, and drug responses. Currently, we are experiencing a genomics bubble, but with advances in understanding biological complexity and the development of enabling technologies, synthetic biology is reviving optimism in many fields, particularly medicine.

BY MICHAEL BROOKS    17 APR, 2014     http://www.newstatesman.com/

Michael Brooks holds a PhD in quantum physics. He writes a weekly science column for the New Statesman, and his most recent book is The Secret Anarchy of Science.

The basic idea is that we take an organism – a bacterium, say – and re-engineer its genome so that it does something different. You might, for instance, make it ingest carbon dioxide from the atmosphere, process it and excrete crude oil.

That project is still under construction, but others, such as using synthesised DNA for data storage, have already been achieved. As evolution has proved, DNA is an extraordinarily stable medium that can preserve information for millions of years. In 2012, the Harvard geneticist George Church proved its potential by taking a book he had written, encoding it in a synthesised strand of DNA, and then making DNA sequencing machines read it back to him.

When we first started achieving such things it was costly and time-consuming and demanded extraordinary resources, such as those available to the millionaire biologist Craig Venter. Venter’s team spent most of the past two decades and tens of millions of dollars creating the first artificial organism, nicknamed “Synthia”. Using computer programs and robots that process the necessary chemicals, the team rebuilt the genome of the bacterium Mycoplasma mycoides from scratch. They also inserted a few watermarks and puzzles into the DNA sequence, partly as an identifying measure for safety’s sake, but mostly as a publicity stunt.

What they didn’t do was redesign the genome to do anything interesting. When the synthetic genome was inserted into an eviscerated bacterial cell, the new organism behaved exactly the same as its natural counterpart. Nevertheless, that Synthia, as Venter put it at the press conference to announce the research in 2010, was “the first self-replicating species we’ve had on the planet whose parent is a computer” made it a standout achievement.

Today, however, we have entered another era in synthetic biology and Venter faces stiff competition. The Steve Jobs to Venter’s Bill Gates is Jef Boeke, who researches yeast genetics at New York University.

Boeke wanted to redesign the yeast genome so that he could strip out various parts to see what they did. Because it took a private company a year to complete just a small part of the task, at a cost of $50,000, he realised he should go open-source. By teaching an undergraduate course on how to build a genome and teaming up with institutions all over the world, he has assembled a skilled workforce that, tinkering together, has made a synthetic chromosome for baker’s yeast.

 

Stepping into DIYbio and Synthetic Biology at ScienceHack

Posted April 22, 2014 by Heather McGaw and Kyrie Vala-Webb

We got a crash course on genetics and protein pathways, and then set out to design and build our own pathways using both the “Genomikon: Violacein Factory” kit and Synbiota platform. With Synbiota’s software, we dragged and dropped the enzymes to create the sequence that we were then going to build out. After a process of sketching ideas, mocking up pathways, and writing hypotheses, we were ready to start building!

The night stretched long, and at midnight we were forced to vacate the school. Not quite finished, we loaded our delicate bacteria, incubator, and boxes of gloves onto the bus and headed back to complete our bacterial transformation in one of our hotel rooms. Jammed in between the beds and the mini-fridge, we heat-shocked our bacteria in the hotel ice bucket. It was a surreal moment.

While waiting for our bacteria, we held an “unconference” where we explored bioethics, security and risk related to synthetic biology, 3D printing on Mars, patterns in juggling (with live demonstration!), and even did a Google Hangout with Rob Carlson. Every few hours, we would excitedly check in on our bacteria, looking for bacterial colonies and the purple hue characteristic of violacein.

Most impressive was the wildly successful and seamless integration of a diverse set of people: in a matter of hours, we were transformed from individual experts and practitioners in assorted fields into cohesive and passionate teams of DIY biologists and science hackers. The ability of everyone to connect and learn was a powerful experience, and over the course of just one weekend we were able to challenge each other and grow.

Returning to work on Monday, we were hungry for more. We wanted to find a way to bring the excitement and energy from the weekend into the studio and into the projects we’re working on. It struck us that there are strong parallels between design and DIYbio, and we knew there was an opportunity to bring some of the scientific approaches and curiosity into our studio.

 

 

Read Full Post »

S-nitrosylation signaling

Author and Curator: Larry H Bernstein, MD, FCAP

 

S-nitrosylation signaling in cell biology.

Gaston BM1, Carver J, Doctor A, Palmer LA

Mol Interv. 2003 Aug; 3(5): 253-63  PMID: 14993439

 

S-Nitrosylated proteins form

  1. when a cysteine thiol reacts with nitric oxide (NO) in the presence of an electron acceptor to form an S-NO bond.
  2. Under physiological conditions, this posttranslational modification affects the function a wide array of cell proteins, ranging from ion channels to nuclear regulatory proteins.

Recent evidence suggests that

1) S-nitrosylated proteins can be synthesized by exposure of specific redox-active motifs to NO,

  • through transnitrosation/transfer reactions, or
  • through metalloprotein-catalyzed reactions;

2) S-nitrosothiols can be sequestered in

  • membranes,
  • lipophilic protein folds, or
  • in vesicles to preserve their activity; and

3) S-nitrosothiols can be degraded by a number of enzymes systems.

These recent insights regarding the

  1. bioactivities,
  2. molecular signaling pathways, and
  3. metabolism of endogenous S-nitrosothiols

have suggested several new therapies for disease ranging from cystic fibrosis to pulmonary hypertension.

 

Key pathways involving NO

Key pathways involving NO

 

Read Full Post »

Music and Movement – the Dynamics of Ubiquitylation

Reporter and Curator: Larry H Bernstein, MD, FCAP

Posted by Biome on 10th July 2013

 

Ubiquitylation is now recognized as

  • comparable in importance to phosphorylation
  • for regulating the activities of cellular proteins;
  • but it is a much more complicated process,
  • involving three enzymes and a sequence of at least four reactions.

Three of these reactions are catalyzed by the first enzyme in the series,

  • the E1 ubiquitin activating enzyme, which undergoes a remarkable sequence
  • of structural rearrangements in the course of passing the small protein ubiquitin
    • from one active site to the next,
  1. to be activated,
  2. thioesterified and
  3. handed off to the next enzyme in the series (the E2),
  4. for further modification and transfer to the target protein.

Ubiquitin is a small, compact protein characterized by a b-grasp fold. As so often with structural studies, homologous proteins from various species have been recruited

  • to build a picture of the structural basis of the E1 mechanism,
  • and the details of E1 structural acrobatics have been worked out

by Brenda Schulman and colleagues from St. Jude Children’s Research Hospital, USA and by Christopher Lima and colleagues from Sloan-Kettering Institute, USA

  • through a collage of pictures largely derived from two different E1s
  • juggling with two different ubiquitin-related small proteins (SUMO and NEDD8).

These are described, with exemplary schematic diagrams, in a recent review in BMC Biology by Sonja Lorenz and colleagues Aaron Cantor, Michael Rape and John Kuriyan from the University of California, Berkeley,

  1. who also discuss the structural flexibility required for transfer to the target by E3 enzymes,
  2. and the exploitation of this flexibility in the regulation of ubiquitin signaling.

Cartoon representations of E1 ubiquitin enzyme in the adenylation state. Image source: Lorenz et al, BMC Biology, 2013, 11:65 The minutiae of structure and mechanism, however, no matter how elegant,

  • do not always lend themselves to lively and engaging prose, and in response to the comment of a referee to this effect,

Lorenz and colleagues have summarized

  • the macromolecular juggling sequence as the E1 passes its substrate from one catalytic site to the next in a video –

with the careful disclaimer that the transitions between the different states captured by the crystal structures are of course hypothetical. The domains light up in color as each comes into play, and

  • the whole thing is set to the score of ‘The juggler’ by Ernst Toch,
  • modified and performed on the piano by first author Sonja Lorenz, and

culminating in a triumphant chord as

  • the E2 enzyme docks into its binding site at the end of the sequence.

BMC Biology | Full text | Macromolecular juggling by ubiquitylation … http://www.biomedcentral.com/1741-7007/11/65‎ by S Lorenz – ‎2013 – ‎ Jun 25, 2013 – BMC Biology 2013, 11:65 doi:10.1186/1741-7007-11-65. The electronic … 2013 Lorenz et al; licensee BioMed Central Ltd. This article is part of the series Ubiquitin signals and beyond. Macromolecular juggling by ubiquitylation enzymes Sonja Lorenz12, Aaron J Cantor12, Michael Rape12 and John Kuriyan12345* BMC Biology 2013, 11:65     http://dx.doi.org/10.1186/1741-7007-11-65 The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1741-7007/11/65

Abstract

The posttranslational modification of target proteins with ubiquitin and ubiquitin-like proteins is accomplished by the sequential action of E1, E2, and E3 enzymes. Members of the E1 and E3 enzyme families can undergo particularly large conformational changes during their catalytic cycles, involving the remodeling of domain interfaces. This enables the efficient, directed and regulated handover of ubiquitin from one carrier to the next one. We review some of these conformational transformations, as revealed by crystallographic studies.

Review

To catalyze multistep reactions some metabolic enzymes undergo major structural rearrangements. By disassembling the interfaces between domains and then reassembling them differently, these enzymes create distinct active sites and recognize multiple substrates sequentially. Having one enzyme that can restructure itself to carry out two or more steps in sequence is presumably more efficient than parsing out the tasks to separate enzymes and also reduces the risk of losing intermediate products, particularly those that are chemically labile. Catherine Drennan and colleagues recently introduced the term ‘molecular juggling’ [1] to describe the large structural rearrangements of enzymes involved with B12-dependent methyl transfer reactions [13]. One of us (JK) encountered a similar phenomenon in the early 1990s when studying the bacterial thioredoxin reductase enzyme [46]. Other examples of molecular juggling are provided by the ANL (acyl-CoA synthetases, non-ribosomal peptide synthetase adenylation domains, and luciferase) superfamily of adenylating enzymes (for review, see [7]). The last decade has seen a dramatic expansion in structural information for a set of enzymes that control the addition of ubiquitin, a small protein, to target proteins. This new structural window into ubiquitylation enzymes has revealed them to be molecular jugglers of a most sophisticated kind, as noted for one class of these enzymes by Christopher Lima and coworkers [8]. In this review we survey what we have learned from crystallographic studies about the large conformational changes in ubiquitylation enzymes. Ubiquitylation controls protein trafficking and degradation as well as complex signaling pathways, such as DNA repair and immune responses (for reviews, see [9,10]). The diverse physiological roles of ubiquitin originate, at least in part, from the many ways by which it can be attached to target proteins. Target proteins may be tagged with one or several individual ubiquitin molecules or with polymeric ubiquitin chains. These chains are linked through isopeptide bonds between the carboxyl terminus of one ubiquitin molecule and a primary amino group on another. Ubiquitin contains seven lysine residues and a free amino terminus, so the chains can have many different topologies, depending on the enzymes involved in assembling them. The various types of ubiquitin modifications are recognized by different downstream effectors in the cell and trigger distinct functional outcomes (for reviews, see [11,12]). Further diversity arises from the existence of several ubiquitin-like protein modifiers, such as SUMO (small ubiquitin-like modifier) and NEDD8 (neural precursor cell expressed, developmentally down-regulated 8) that utilize their own enzymatic machineries and are associated with distinct physiological responses (for review, see[13]). We shall draw on structural information from studies on all three of these modifiers, and will, where appropriate, refer to ubiquitin and ubiquitin-like proteins collectively as ‘Ubl’. Ubiquitylation is accomplished through a catalytic cascade involving ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin ligases (E3) (for review, see [14]). The human proteome contains two E1 enzymes [1518], approximately 40 E2 enzymes [19], and over 600 E3 enzymes [20], the combination of which accounts for the large variety of ubiquitin modifications. To transfer ubiquitin from one carrier to the next one, ubiquitylation enzymes sequentially form and reorganize protein-protein interfaces. We thus use the term ‘macromolecular juggling’ to describe these actions. E1 enzymes catalyze the formation of a thioester-linked complex between ubiquitin and E2 enzymes (for review, see [14]) (Figure 1a). This process begins by activation of the carboxyl terminus of ubiquitin by adenylation, followed by a thioesterification reaction in which ubiquitin is conjugated to a cysteine residue at the active site of the E1 enzyme. Ubiquitin is then transferred to the active site cysteine of an E2 enzyme in a trans-thioesterification reaction. 1741-7007-11-65-1  fig 1. Ubiquitylation is a multistep reaction Figure 1. Ubiquitylation is a multistep reaction. (a) E1 enzymes use ATP to activate the carboxyl terminus of ubiquitin (Ubi) as a high-energy anhydride (Ubi-AMP). The E1 active site cysteine then attacks the adenylated ubiquitin to form a thioester intermediate. Subsequently, the active site cysteine of the E2 receives ubiquitin via trans-thioesterification. (b) E3 enzymes catalyze the formation of an isopeptide bond between the ubiquitin carboxyl terminus and a primary amino group of an acceptor. The acceptor can be a target protein (mono-ubiquitylation/ubiquitin chain initiation) or another ubiquitin molecule (ubiquitin chain elongation). Catalysis by HECT- and RBR-type E3 enzymes proceeds through an intermediate, in which the ubiquitin carboxyl terminus is thioester-linked to a cysteine residue at the active site of the E3, followed by aminolysis of the thioester. In contrast, RING-type E3s catalyze direct transfer of ubiquitin from the E2 active site cysteine to amino groups on the acceptor. The transfer of ubiquitin from ‘charged’ E2 enzymes onto target proteins is mediated by enzymes of the E3 family. The common outcome of E3-catalyzed reactions is an isopeptide linkage between the carboxyl terminus of ubiquitin and a primary amino group on a target protein. However, E3 enzymes vary significantly in size and subunit composition and follow different mechanisms (for reviews, see [21,22]): RING (really interesting new gene) domain-containing E3 enzymes and the related U-box E3s interact with charged E2 enzymes and target proteins simultaneously and facilitate direct ubiquitin transfer from the E2 onto the target protein (Figure 1b). In contrast, the mechanism of HECT (homologous to the E6-AP C-terminus) domain-containing E3 enzymes includes an additional trans-thioesterification step, in which ubiquitin is linked to a catalytic cysteine on the E3. The resulting charged E3 then transfers ubiquitin to the target protein (Figure 1b). A combination of both mechanisms is used by the RING-in-between-RING (RBR) family of E3s. Like HECT E3s, RBRs contain a catalytic cysteine and form a thioester-linked intermediate with ubiquitin before passing it on to the target protein [23] (Figure 1b). However, they also utilize a canonical RING domain to recruit the charged E2 enzyme (for review, see [22]). As revealed by a growing body of structural data, E1 and E3 enzymes undergo striking remodeling of domains during their catalytic cycle. In contrast, most E2 enzymes are relatively small, single-domain proteins and do not utilize large-scale structural changes for Ubl transfer [2426]. We describe the conformational changes of E1 and HECT-type E3 enzymes in the first part of this review. Unlike E2 or RING-type E3 enzymes, these two classes of ubiquitylation enzymes catalyze multistep reactions. Structural rearrangements allow these enzymes to bind multiple sequential substrates and process them in distinct active sites. As reviewed elsewhere [27,28], structural flexibility has also been observed in cullin-RING ligases, a group of multisubunit RING-type E3 enzymes, which catalyze one-step ubiquitin transfer reactions. In the second part, we describe conformational changes that are involved in modulating the activity of ubiquitylation enzymes. Such regulatory rearrangements are perhaps best understood for E3 enzymes. We have chosen to focus on the way structural flexibility is exploited in the regulation of the single-subunit RING E3 Cbl [29,30].

E1 enzymes reorganize domains during their catalytic cycle

The catalytic mechanism of E1 enzymes includes three reactions that require distinct active site environments: (i) adenylation, (ii) thioesterification, and (iii) trans-thioesterification. Our current understanding of the conformational changes that canonical E1 enzymes undergo during catalysis stems primarily from crystallographic studies carried out by the groups of Brenda Schulman [3136], Christopher Lima [8,37] and Hermann Schindelin [38]. These studies were performed with different E1 enzymes that operate on ubiquitin and its close relatives, SUMO and NEDD8, respectively. All three of these E1s appear to follow a conserved general mechanism of catalysis, and because of their related domain structures they are classified as ‘canonical’ (for review, see[39]). In contrast, ‘non-canonical’ E1 enzymes, such as the one that is specific for the autophagy-related Ubls ATG8 and ATG12 have distinct structures and mechanisms [4043]. Canonical E1 enzymes contain two Rossmann-type folds (either as domains within the same polypeptide chain or as separate subunits in the context of a heterodimer), a domain containing the catalytic cysteine (the cysteine domain), and a ubiquitin-fold domain [31,37,38] (for review, see [39]) (Figure 2). The two Rossmann-type subunits are functionally distinct and form a quasi-symmetric dimer that catalyzes the modification of a single Ubl molecule at a time. Only one subunit, the ‘active’ Rossmann-type subunit, binds the ATP that is required for adenylation of the terminal carboxyl group of the Ubl. Topologically, the cysteine domain is inserted into the active Rossmann-type subunit. The two connections between the cysteine domain and the Rossmann-type subunit are known as the ‘crossover’ and ‘re-entry’ loops and have an important role in enabling the movement of the cysteine domain during catalysis [8]. The ubiquitin-fold domain contributes to the recruitment of the E2 enzyme onto which the E1-bound Ubl is transferred in a trans-thioesterification reaction [31,34,37,38]. 1741-7007-11-65-2  Fig 2. Conformational rearrangements in E1 enzymes. Figure 2. Conformational rearrangements in E1 enzymes. Cartoon representations of distinct states in the catalytic cycle of canonical E1 enzymes. (a) The adenylation state based on the crystal structure of NAE1-UBA3 in complex with NEDD8 and ATP/Mg2+ [PDB: 1R4N] [32]. The carboxy-terminal tail of the Ubl is in the adenylation site of the active Rossmann-type subunit of the E1, ready to nucleophilically attack the α-phosphate of the ATP to form the Ubl-AMP intermediate. The catalytic cysteine residue in the E1 cysteine domain is part of an α-helix and is removed from the adenylation site, giving rise to an open conformation of the cysteine domain. (b) The thioesterification state as seen in a crystal structure of SAE1-UBA2 and SUMO covalently coupled to an AMP analogue that mimics the tetrahedral intermediate generated during thioesterification [PDB: 3KYD] [8]. Mediated by large conformational changes in the crossover and re-entry loops, the cysteine domain is rotated with respect to the Rossmann-type subunits. The helix containing the active site cysteine seen in (a) has melted. In this closed conformation of the cysteine domain, the catalytic cysteine nucleophile is in position to attack the adenylated carboxyl terminus of the Ubl. The positive dipole of helix H2 in the active Rossmann-type subunit (colored purple) is thought to favor this reaction[8]. (c) The trans-thioesterification state as represented by a crystal structure of NAE1-UBA3 thioester-linked to NEDD8 and in complex with an additional NEDD8 molecule, an E2 enzyme (Ubc12) and ATP/Mg2+[35]. The cysteine domain of the E1 adopts an open orientation similar to the adenylation state (a), but now holds the carboxyl terminus of the thioester-linked Ubl close to the E2 active site (a Cys-to-Ala mutant of the E2 was used in this study (see text)). The ubiquitin-fold domain has swung away from its position in the previous states (a,b) to accommodate the E2 and contributes to E2 binding. In (a,c) domains found in NAE1-UBA3 but not in SAE1-UBA2 were omitted for clarity. To see a rendition of a dynamic transition between the structures shown in the lower panels of (a-c), see Additional file 1. As noted in the movie legend, the details of the trajectory linking individual structures is not realistic and is simply meant to illustrate the nature of the conformational changes rather than identify the nature of the transition pathway. An impressive range of crystallographic snapshots of various catalytic stages of canonical E1 enzymes have outlined the conformational dynamics in this enzyme family [8,31,32,35,37,38,44]. Below, we describe the major structural changes that facilitate the three chemically distinct reaction steps.

Macromolecular juggling by ubiquitylation enzymes

Macromolecular juggling by ubiquitylation enzymes. Format: MP4 Size: 41.9MB Download file

The E1 cysteine domain adopts an open conformation during Ubl adenylation

E1 enzymes initially activate the carboxyl terminus of their Ubl substrates by adenylation. In this reaction, the terminal carboxylate of the Ubl attacks the α-phosphate of ATP bound to the active Rossmann-type subunit, releasing pyrophosphate and generating a Ubl-AMP conjugate. The first structural insights into Ubl recognition by E1 enzymes came indirectly, from studies on their bacterial ancestors, MoeB and ThiF. These proteins participate in the biosynthesis of molybdenum cofactor and thiamine by adenylating the carboxyl terminus of the ubiquitin-fold proteins MoeD and ThiS, respectively [4551]. Unlike canonical E1 enzymes, MoeB and ThiF contain two catalytically active Rossmann-type subunits [4951]; the structural details of their binding to ubiquitin-fold proteins are, however, conserved (for review, see [52]). Ubl recognition by E1 enzymes involves hydrophobic contacts between residues in the active Rossmann-type subunit and a hydrophobic patch on the globular core of the Ubl [32,37,38]. The carboxy-terminal flexible tail of the Ubl protrudes into a shallow cleft on the E1 surface and points toward the ATP binding pocket (Figure 2a), where it is clamped tightly by the crossover loop connecting the cysteine domain and the active Rossmann-type subunit. The ATP binding pocket itself is solvent-accessible, which allows the pyrophosphate product of the adenylation reaction to diffuse out, thereby reducing back-reactions. Residues critical for ATP/Mg2+ binding and catalysis are highly conserved [31,32,37,38,49,51], but contacts between the Ubl tail and the crossover loop vary across different E1 enzymes, and contribute to their specificity for particular Ubls [32,36,5355]. Ubiquitin- and NEDD8-specific E1 enzymes form additional electrostatic contacts with their Ubls, which are mediated by unique domains found in these enzymes [32,38]. During the adenylation reaction, the cysteine domain of the E1 adopts an open conformation in which it makes few contacts with the active Rossmann-type subunit, and the catalytic cysteine residue is separated from the carboxyl terminus of the bound Ubl by over 30 Å [8,32,37,38]. In the subsequent thioesterification reaction, however, the catalytic cysteine residue is linked to the Ubl carboxyl terminus. To accomplish this, the E1 enzyme must either allow release of the Ubl and diffusion towards the catalytic cysteine or, as is the case, major domain rearrangements around the bound Ubl.

The E1 cysteine domain adopts a closed conformation for thioesterification

How E1 enzymes switch between conformations that facilitate adenylation and thioesterification, respectively, was revealed by Christopher Lima, Derek Tan and colleagues. They used a chemical strategy to trap a covalent complex, in which the SUMO-specific E1 enzyme (SAE1-UBA2), SUMO and an AMP analogue are linked covalently to each other in such a way that the active site environment mimics the environment around the tetrahedral intermediate that is formed during the nucleophilic attack by the catalytic cysteine of the E1 on the adenylated SUMO tail (Protein Data Bank (PDB) accession [PDB: 3KYD]) [8]. The E1 cysteine domain in this complex is rotated by approximately 130° with respect to the open state, now adopting a ‘closed’ conformation, in which it forms extensive contacts with the active Rossmann-type subunit (Figure 2b). Large conformational rearrangements also occur in the crossover and re-entry loops connecting the cysteine domain to the active Rossmann subunit, and several structural elements in the cysteine domain and in both Rossmann-type subunits become disordered. In particular, the region of the cysteine domain that bears the catalytic cysteine is helical in the open state, but becomes extended in the closed conformation, enabling the cysteine to reach into the adenylation pocket. How does the active site environment in the closed conformation of the cysteine domain stimulate the thioesterification reaction? In principle, one would expect the presence of basic residues that could promote the deprotonation of the cysteine nucleophile. Surprisingly, however, the active site environment in the closed state does not contain any side chains that could potentially act as general acid/base catalysts. Instead, it places the catalytic cysteine residue near the amino-terminal end of helix H2 of the active Rossmann-type subunit (Figure 2b). Lima and coworkers propose that the positive H2 helix dipole electrostatically stabilizes the transition states of both the adenylation and the thioesterification reactions [8].

Ubl transfer to the E2 requires reorientation of the ubiquitin-fold domain

Before the Ubl protein is passed from the catalytic cysteine of the E1 to that of the E2, a second Ubl protein is adenylated by the E1 [56,57]. The E1 enzyme thus becomes loaded with two Ubl proteins, one that is thioester-linked to the catalytic cysteine of the E1 and a second one bound non-covalently in the adenylation site. Interestingly, binding of the second Ubl protein at the adenylation site of the E1 facilitates the transfer of the thioesterified Ubl protein to the E2 enzyme[58]. The structural basis for this coupling between the two Ubls was revealed by Brenda Schulman and colleagues, who solved a crystal structure of the doubly loaded state of the NEDD8-specific E1 (NAE1-UBA3) in complex with a cognate E2 enzyme (Ubc12) [PDB: 2NVU] [35]. To trap this state and prevent NEDD8 transfer onto the E2 enzyme, the catalytic cysteine residue of the E2 was replaced by alanine. In this structure the E1 cysteine domain adopts an open conformation, thereby removing the thioester-linked Ubl from the adenylation site, as required for binding of the second Ubl protein in this site. To accommodate the re-oriented thioester-linked Ubl and the E2 enzyme, the ubiquitin-fold domain of the E1 undergoes a large outward swing with respect to the Rossman-type subunits (Figure 2c). The E2 enzyme is recognized in tripartite fashion by the doubly loaded E1 enzyme [35]: one set of interactions is contributed by the ubiquitin-fold domain of the E1, a second set is provided by the active Rossmann-type subunit, and the third involves the Ubl that is thioester-linked to the active site of the cysteine domain. Upon Ubl transfer from the E1 catalytic cysteine to the E2, one face of the tripartite interaction between the E1 and the E2 is lost: the Ubl, now linked to the E2, no longer provides a covalent tether to the E1. The resulting decrease in affinity between E1 and E2 presumably facilitates a backward swing of the ubiquitin-fold domain of the E1, thereby enabling product release. The conformational switch of the ubiquitin-fold domain, together with the tripartite, Ubl-assisted nature of E2 binding, thus adds directionality to the trans-thioesterification reaction. In line with this mechanism, mutations that restrict the freedom of movement of the ubiquitin-fold domain decrease the efficiency of Ubl transfer onto the E2 [34,38]. Contacts between the ubiquitin-fold domain and the E2 enzyme also contribute to the specificity of E1 enzymes for particular Ubls [16,5961] (for review, see [39]). Notably, the crystallographic snapshot of doubly loaded E1 in complex with the E2 leaves an estimated approximately 20 Å gap between the active site cysteine residues of the E1 and the E2[35], indicating that trans-thioesterification occurs in another, yet uncharacterized, conformation.

HECT E3 enzymes require structural plasticity for catalysis

Once ubiquitin has been linked to the E2 enzyme, an E3 enzyme catalyzes the transfer of ubiquitin to a target protein. For E3s in the HECT and RBR families, this process involves the formation of an intermediate in which ubiquitin is thioester-linked to a catalytic cysteine residue of the E3 (Figure 1b). Like E1 enzymes, these E3 enzymes thus catalyze multistep reactions. Nikola Pavletich and coworkers [62] predicted considerable structural flexibility in HECT E3 enzymes when they determined the first crystal structure of a HECT family member, the HECT domain of E6AP in complex with the E2 enzyme UbcH7 [PDB: 1C4Z]. HECT domains (approximately 40 kDa) consist of two lobes, a large amino-terminal or N-lobe containing the E2 binding site and a smaller carboxy-terminal or C-lobe bearing the catalytic cysteine. In the E2-bound state, the two lobes of E6AP were found to adopt an open, ‘L’-shaped conformation, giving rise to a >40 Å gap between the active site cysteine residues of the E2 and the E3 (Figure 3a). Transfer of ubiquitin between these sites was thus expected to involve conformational rearrangements. 1741-7007-11-65-3  Fig 3. Swinging domains in HECT E3 enzymes Figure 3. Swinging domains in HECT E3 enzymes. Cartoon representations of crystal structures of various HECT domains. (a) Open, ‘L’-shaped conformation of E6AP (E3) in complex with UbcH7 (E2) [PDB: 1C4Z] [62], (b) closed, ‘T’-shaped conformation of WWP1/AIP [PDB: 1ND7] [63], and (c) trans-thioesterification complex of NEDD4L with a ubiquitin-E2 (UbcH5B) conjugate [PDB:3JVZ] [64]. In (c) the E2 active site cysteine was mutated to serine (colored yellow in our representation), resulting in an oxy-ester linkage with ubiquitin in lieu of the native thioester. (d) Distinct classes of C-lobe orientations based on the crystal structures of various HECT domains (WWP1/AIP [PDB: 1ND7], Itch [PDB: 3TUG], HUWE1 [PDB: 3G1N, 3H1D], NEDD4L [PDB: 2ONI, 3JVZ], E6AP [PDB: 1C4Z], Rsp5 [PDB: 3OLM], Smurf2 [PDB: 1ZVD], NEDD [PDB: 2XBB]). A second unique C-lobe orientation observed for NEDD [PDB: 2XBF] could not be displayed for clarity. In our representation the HECT N-lobes are superimposed and only one of them is displayed. Binding partners, such as E2 enzymes or ubiquitin, found in some of the structures are not displayed. Indeed, the two lobes are fundamentally reorganized with respect to each other in a crystal structure of the HECT domain of WWP1/AIP solved by Joseph Noel and colleagues [PDB: 1ND7][63]. This HECT domain adopts a closed conformation, reminiscent of the letter ‘T’ (Figure 3b). A flexible hinge region connecting the two HECT lobes enables this remarkable rearrangement, and mutations that restrict conformational freedom in this region inhibit the ubiquitylation activity of WWP1/AIP in vitro, attesting to the functional importance of structural flexibility in this enzyme[63]. The transition from the open to the closed state of the HECT domain is expected to bring the active sites of the E3 and a bound E2 closer to each other. However, a remaining gap of approximately 17 Å between the catalytic centers of E2 and E3 (estimated from the crystal structure of WWP1/AIP and modeling of the E2 according to the E6AP-UbcH7 structure [62]) indicated additional conformational changes yet to be uncovered that would allow trans-thioesterification. Key insights into these structural changes came from Brenda Schulman’s group, who determined a crystal structure of the HECT-domain of NEDD4L in complex with a thioester-linked E2-ubiquitin conjugate [PDB: 3JVZ] [64]. The complex adopts a compact conformation, in which the HECT C-lobe is rotated markedly compared to previous structures, and makes contacts with E2-bound ubiquitin (Figure 3c). This interaction is mediated by a conserved hydrophobic surface on the C-lobe of the E3 and appears to tether the C-lobe in proximity to the E2 – as was hypothesized by Pavletich and colleagues [62]. A remaining gap of approximately 8 Å between the catalytic centers of E2 and E3 in this structure could readily be closed by additional small rotations around the flexible hinge region, yielding a functional trans-thioesterification intermediate. Crystal structures of several other HECT domains are now available, including ‘open-like’ states of Rsp5 [PDB: 3OLM] [65] and Smurf2 [PDB: 1ZVD] [66], closed states of Itch [PDB: 3TUG] and HUWE1 [PDB: 3G1N, 3H1D] [67], two unique states of NEDD4 [PDB: 2XBF, 2XBB] [68], and NEDD4L in an apo conformation that resembles its trans-thioesterification state with ubiquitin-charged E2 [PDB: 2ONI] (Figure 3d). Taken together, these HECT domain structures show a considerable variation in the relative orientations of N- and C-lobes, indicating that dynamic rearrangements are a common feature in the HECT E3 family. Interestingly, the same is true for HECT E3-like proteins found in bacterial pathogens [6971]. These bacterial proteins can interact with eukaryotic E2 enzymes in vitro and are thought to ‘hijack’ the ubiquitylation system upon delivery into the cytosol of the eukaryotic host, thereby regulating host inflammatory responses[69]. The structural plasticity of HECT-like E3 enzymes in both eukaryotic and prokaryotic systems is consistent with a functional role for this level of flexibility during catalysis. It is possible that domain movements of HECT E3s are implicated in the iterative binding and release of E2 enzymes or the repositioning of ubiquitin substrates, as might be required during the formation of a ubiquitin chain [63,64]. The mechanism of ubiquitin chain formation by HECT E3 enzymes, however, remains controversial and is likely to vary between enzymes [72,73].

The structural flexibility of E3 enzymes is harnessed for their regulation

Since E3 enzymes require flexibility during their catalytic cycle, they can be regulated by processes that restrict their flexibility and lock them in particular conformations. The HECT E3s Itch and Smurf2, for example, are negatively regulated through intra- and intermolecular interactions between their catalytic HECT domains and preceding WW and C2 domains, respectively [74,75]. Autoinhibition is relieved upon phosphorylation in the amino-terminal part of Itch [74] and binding of Smurf2 to the adaptor protein Smad7, respectively [75]. Autoinhibitory domain interactions have also been identified for E3 enzymes in the RBR [76] and RING families (for review, see [77]). A structural mechanism for regulation of RING-type E3 enzymes by posttranslational modifications was first described for the multisubunit cullin-RING ligases. As suggested by biochemical studies indicative of conformational rearrangements [78,79], covalent attachment of the Ubl NEDD8 to the cullin subunit results in a dramatic re-orientation of the RING domain that places the bound E2 adjacent to the substrate, thereby activating the ligase [80]. This conformational switch is harnessed by various cellular effectors that restrict the conformational flexibility of cullin-RING ligases (for reviews, see [28,77]). Other RING-type E3 enzymes are regulated through conformational changes that affect their oligomerization state, as demonstrated for inhibitor of apoptosis proteins (IAPs) [81,82] and tumor necrosis factor receptor-associated factor (TRAF6)[83]. We will focus here on the recently elucidated role of phosphorylation-induced structural rearrangements in the regulation of the single-subunit RING E3 enzyme Cbl.

Phosphorylation triggers regulatory domain rearrangements in CBL proteins

Cbl proteins (c-Cbl, Cbl-b and Cbl-c) are a family of single-subunit RING E3 enzymes that ubiquitylate receptor and non-receptor tyrosine kinases and thereby regulate both the trafficking and the degradation of these kinases (for reviews, see [84,85]). Members of the Cbl family share a conserved amino-terminal tyrosine kinase binding module that includes an SH2 (Src homology 2) domain, as shown by Michael Eck and colleagues [86,87], and is connected to the RING domain through a helical linker. The SH2 domains of Cbl proteins bind to phosphorylated tyrosine residues on substrates, including receptor-tyrosine kinases such as the epidermal growth factor receptor[88] and the T-cell receptor-associated tyrosine kinase Zap70 [86,89]. The RING domain recruits the E2 enzyme (for review, see [90]). The first view of how RING domains recognize E2 enzymes was provided by Nikolai Pavletich and coworkers [91], who determined the crystal structure of the tyrosine kinase binding module, linker helix and RING domain of c-Cbl in complex with a phosphorylated Zap70-derived peptide and the E2 enzyme UbcH7 [PDB: 1FBV] (Figure 4b). However, this structure showed a large gap between the E2 active site and the substrate peptide, and with no information on the spatial orientation of the target protein with respect to this peptide, it remained unclear how ubiquitin is transferred to the target. Moreover, although the co-crystal structure of c-Cbl and UbcH7 represents a canonical E2-E3 complex, UbcH7 and c-Cbl do not form an active and physiologically relevant E2-E3 pair [92,93]. Another structural puzzle arose from the discovery that phosphorylation of Cbl proteins in the linker helix region increases their ubiquitin ligase activity [88,9496]. Phosphorylation is incompatible with the conformation observed in the first crystal structures because the modification site, Tyr371 in c-Cbl, is buried at the interface of the tyrosine kinase binding module and the helical linker region (Figure 4b). 1741-7007-11-65-4  Fig 4. Regulatory rearrangements in Cbl proteins. Figure 4. Regulatory rearrangements in Cbl proteins. (a) ‘Closed’ conformation of Cbl based on the crystal structure of the apo c-Cbl amino-terminal region, comprising the tyrosine kinase binding module, the helical linker region, and the RING domain [PDB: 2Y1M] [29]. The regulatory tyrosine, Y371, located in the helical linker region, is buried in a hydrophobic core formed by the SH2 domain and the four-helix bundle in the tyrosine kinase binding module.(b) ‘Partially open’ conformation of Cbl based on the co-crystal structure of c-Cbl amino-terminal region with a ZAP70-derived phosphopeptide and the E2 enzyme UbcH7 [PDB: 1FBV][91]. Phosphopeptide binding induces a shift in the SH2 domain that perturbs the interface between the helical linker and the tyrosine kinase binding module, probably favoring dissociation of the RING domain from the tyrosine kinase binding module and thus increasing the accessibility of the E2 binding surface. (c) ‘Open’ conformation of Cbl based on the co-crystal structure of phosphorylated c-Cbl bound to a ZAP7-derived phosphopeptide and UbcH5B [PDB: 4A4C] [29]. The phosphorylated regulatory tyrosine, Tyr371, interacts with residues in the E2 binding surface of the RING domain. The RING domain is situated on the opposite side of the tyrosine kinase binding module compared to (b). Two independent studies have recently shed light on this discrepancy and have revealed the central role of conformational plasticity in Cbl regulation. Danny Huang and colleagues [29] presented three crystal structures of a c-Cbl fragment comprising the tyrosine kinase binding module, the helical linker region and the RING domain: (i) the apo form [PDB: 2Y1M], (ii) c-Cbl bound to a phosphorylated Zap70-derived peptide [PDB: 2Y1N], and (iii) phosphorylated c-Cbl in a ternary complex with the phosphorylated Zap70-derived peptide and the E2 enzyme UbcH5B [PDB: 4A4B]. Fuyuhiko Inagaki and coworkers [30] provided nuclear magnetic resonance (NMR) and small-angle X-ray scattering (SAXS) data on Cbl-b supporting the existence of distinct conformations in solution and highlighting the flexible nature of Cbl family proteins. In the absence of substrate, Cbl favors a compact, autoinhibited, ‘closed’ conformation, in which contacts between the tyrosine kinase binding module and the RING domain obstruct the E2 binding site [29,30] (Figure 4a). Binding of substrate peptide to the SH2 domain perturbs the closed conformation, which releases the RING domain and opens up the E2 binding site [29,30]. This ‘partially open’ state, as represented by the previous c-Cbl-UbcH7 co-crystal structure [91], shows a tight association between the linker helix region and the tyrosine kinase binding module (Figure 4b). In solution, however, the partially open state is in a dynamic equilibrium with other conformations that make the regulatory tyrosine residue accessible [30]. Phosphorylation at this site stabilizes a ‘fully open’ state, in which the helical linker region is completely dissociated from the tyrosine kinase binding module and instead makes contact with the RING domain [29,30] (Figure 4c). The phosphorylated tyrosine on the linker helix forms ionic interactions with lysine residues on the RING domain, whose positive charge might otherwise repel the positively charged binding surface of the E2 [30]. The RING domain also undergoes a dramatic re-orientation relative to the tyrosine kinase binding module, which significantly reduces the distance between the E2 active site and the bound substrate peptide [29]. Taken together, the conformational opening thus increases the affinity of Cbl proteins for E2 enzymes as well as their catalytic efficiency of ubiquitin transfer. While these studies reveal how posttranslational modifications and allosteric effects can induce a shift in the conformational equilibrium of Cbl proteins, it is not the end of the story. For c-Cbl and Cbl-b, dimerization through their carboxy-terminal ubiquitin-associated (UBA) domain is required for them to function in cells [9799]. This raises the intriguing question of whether dimerization of Cbl proteins allows them to detect and respond to the dimerization or clustering of receptor-tyrosine kinases upon activation.

Catalytic efficiency and regulation through macromolecular juggling In this review we have highlighted a few of the many impressive crystallographic studies delineating the large-scale conformational changes that underlie the catalytic action and regulation of ubiquitylation enzymes. E1 enzymes reorganize the three-dimensional arrangement of their domains to generate the active site environments for chemically distinct reactions and to progressively alter the affinities for their sequential macromolecular substrates. These features presumably allow E1 enzymes to achieve efficiency and directionality in the catalysis of multistep reactions. Similar mechanisms are likely to be used by enzymes in the HECT E3 family, which also rely on structural flexibility to catalyze multistep reactions. Moreover, conformational rearrangements are important in ubiquitylation enzymes that catalyze one-step reactions, as seen for members of the cullin-RING family. These multisubunit E3 enzymes re-orient individual subunits to allow the RING domain to approach target proteins of various sizes and to enable the formation of ubiquitin chains [100102] (for reviews, see [27,28]). Structural studies on a particularly complex cullin-RING E3, the anaphase-promoting complex, are beginning to reveal how conformational changes in this giant, approximately 1.5 megadalton protein assembly affect function [103,104].

The need to efficiently process macromolecular substrates unites the various components of the ubiquitylation machinery, irrespective of their size and complexity. Unlike small metabolites that often interact with small surface crevices that can be opened or closed through relatively subtle structural fluctuations, protein substrates typically utilize large, flat surfaces to bind to enzymes. To modulate these surfaces and to actually juggle protein substrates without either holding on to them too long or dropping them prematurely presents a considerable challenge. Large-scale conformational rearrangements appear to have emerged as an evolutionary answer.

Note

While this review was in press, Shaun Olsen and Christopher Lima published the crystal structure of a complex containing Schizosaccharomyces pombe E1 (Uba1), E2 (Ubc4), and ubiquitin that illuminates the structural basis of the final trans-thioesterification step in the catalytic cycle of canonical E1 enzymes [105].

Abbreviations

PDB: Protein data bank.

Acknowledgements

We acknowledge support by a Leukemia and Lymphoma Society postdoctoral fellowship award (SL) and a University of California Cancer Research Coordinating Committee Graduate Fellowship (AJC). We thank Dr Tiago Barros for assistance with preparation of the movie.

References
  1. Kung Y, Ando N, Doukov TI, Blasiak LC, Bender G, Seravalli J, Ragsdale SW, Drennan CL:Visualizing molecular juggling within a B12-dependent methyltransferase complex.

Nature 2012, 484:265-269. PubMed Abstract | Publisher Full Text | PubMed Central Full Text

  1. Bandarian V, Pattridge KA, Lennon BW, Huddler DP, Matthews RG, Ludwig ML: Domain alternation switches B(12)-dependent methionine synthase to the activation conformation.

Nat Struct Biol 2002, 9:53-56. PubMed Abstract | Publisher Full Text

  1. Bandarian V, Ludwig ML, Matthews RG: Factors modulating conformational equilibria in large modular proteins: a case study with cobalamin-dependent methionine synthase.

Proc Natl Acad Sci U S A 2003, 100:8156-8163. PubMed Abstract | Publisher Full Text |PubMed Central Full Text

  1. Kuriyan J, Krishna TS, Wong L, Guenther B, Pahler A, Williams CH, Model P: Convergent evolution of similar function in two structurally divergent enzymes.

Nature 1991, 352:172-174. PubMed Abstract | Publisher Full Text

  1. Waksman G, Krishna TS, Williams CH, Kuriyan J: Crystal structure of Escherichia coli thioredoxin reductase refined at 2 A resolution. Implications for a large conformational change during catalysis.

J Mol Biol 1994, 236:800-816. PubMed Abstract | Publisher Full Text

  1. Lennon BW, Williams CH, Ludwig ML: Twists in catalysis: alternating conformations of Escherichia coli thioredoxin reductase.

Science 2000, 289:1190-1194. PubMed Abstract | Publisher Full Text

  1. Gulick AM: Conformational dynamics in the Acyl-CoA synthetases, adenylation domains of non-ribosomal peptide synthetases, and firefly luciferase.

ACS Chem Biol 2009, 4:811-827. PubMed Abstract | Publisher Full Text |PubMed Central Full Text

  1. Olsen SK, Capili AD, Lu X, Tan DS, Lima CD: Active site remodelling accompanies thioester bond formation in the SUMO E1.

Nature 2010, 463:906-912. PubMed Abstract | Publisher Full Text | PubMed Central Full Text

  1. Varshavsky A: The Early History of the Ubiquitin Field.

Protein Sci 2006, 15:647-654. PubMed Abstract | Publisher Full Text |PubMed Central Full Text 10. Haglund K, Dikic I: Ubiquitylation and cell signaling. EMBO J 2005, 24:3353-3359. PubMed Abstract | Publisher Full Text |PubMed Central Full Text 11. Komander D: The emerging complexity of protein ubiquitination. Biochem Soc Trans 2009, 37:937-953. PubMed Abstract | Publisher Full Text 12. Kulathu Y, Komander D: Atypical ubiquitylation – the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat Rev Mol Cell Biol 2012, 13:508-523. PubMed Abstract | Publisher Full Text 13 van der Veen AG, Ploegh HL: Ubiquitin-like proteins. Annu Rev Biochem 2012, 81:323-357. PubMed Abstract | Publisher Full Text 14 Hershko A, Ciechanover A: The ubiquitin system. Annu Rev Biochem 1998, 67:425-479. PubMed Abstract | Publisher Full Text 15 Handley PM, Mueckler M, Siegel NR, Ciechanover A, Schwartz AL: Molecular cloning, sequence, and tissue distribution                        of the human ubiquitin-activating enzyme E1.         Proc Natl Acad Sci U S A 1991, 88:258-262. PubMed Abstract | Publisher Full Text |PubMed Central Full Text

Read Full Post »

« Newer Posts